GZR101 vs IcoSema

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

GZR101

Developed by Gan & Lee Pharmaceuticals

Phase 2 in Type 2 Diabetespeptide
Partial signal

NCT06199505 · Phase 2 · completed

The study used randomization and an active comparator, but it was open-label and had a surrogate primary endpoint—change in HbA1c rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2027 · NCT07387003 (registry estimate)

Reported efficacy

Change in HbA1c (Baseline to week 16): Change in HbA1c from baseline to week 16: Part A GZR101 once-daily -1.56% vs IDegAsp once-daily -1.31% (difference -0.24%); Part B GZR101+aspart once-daily -1.64% and twice-daily -1.68% vs IDegAsp twice-daily -1.59% (differences -0.06% and -0.09%). (met)

Result source: NCT06199505

IcoSema · Kyinsu

Marketed by Novo Nordisk

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT05352815 · Phase 3 · completed

Participants were randomized 1:1 to IcoSema or active insulin icodec, but the study was open-label rather than blinded. The primary HbA1c endpoint was statistically significantly better with IcoSema, although HbA1c is a surrogate metabolic measure rather than a hard clinical endpoint.

Reported efficacy

Change in glycated haemoglobin (HbA1c) (From baseline (week 0) to week 40): (-3·32 vs -2·44 percentage points; estimated treatment difference [ETD] -0·88 percentage points [95% CI -1·12 to -0·63]), confirming superiority of IcoSema (p<0·001) (met)

Result source: NCT06269107

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGZR101IcoSema
HbA1c, change-1.6% vs -1.3%avs IDegAsp once-dailywk 16NCT06199505
2 other results
-1.6% vs -0.9%vs Insulin Icodecwk 52 · n 598NCT05352815
2 other results
  • -1.4% vs -0.9% wk 52 · n 325 · Phase 3 · primary NCT05259033
  • -1.5% vs -1.4% wk 52 · Phase 3 · primary NCT05013229
Body weight, change (kg)—Not reported-3.7 vs 2.0vs Insulin Icodecwk 52 · n 606NCT05352815
1 other result
  • 0.9 vs -3.8 wk 52 · n 325 · Phase 3 · secondary NCT05259033
HbA1c below 7%—Not reported—Not posted · NCT05013229
Fasting plasma glucose, change—Not reported-1.9 vs -1.6vs Insulin Icodecwk 52 · n 552NCT05352815
1 other result
  • -2.7 vs -1.4 wk 52 · n 313 · Phase 3 · secondary NCT05259033
3-point MACE (% with event)—Not reported—Not posted · NCT05013229

HbA1c, change

GZR101
-1.6% vs -1.3%avs IDegAsp once-dailywk 16NCT06199505
2 other results
IcoSema
-1.6% vs -0.9%vs Insulin Icodecwk 52 · n 598NCT05352815
2 other results
  • -1.4% vs -0.9% wk 52 · n 325 · Phase 3 · primary NCT05259033
  • -1.5% vs -1.4% wk 52 · Phase 3 · primary NCT05013229

Body weight, change (kg)

GZR101
—Not reported
IcoSema
-3.7 vs 2.0vs Insulin Icodecwk 52 · n 606NCT05352815
1 other result
  • 0.9 vs -3.8 wk 52 · n 325 · Phase 3 · secondary NCT05259033

HbA1c below 7%

GZR101
—Not reported
IcoSema
—Not posted · NCT05013229

Fasting plasma glucose, change

GZR101
—Not reported
IcoSema
-1.9 vs -1.6vs Insulin Icodecwk 52 · n 552NCT05352815
1 other result
  • -2.7 vs -1.4 wk 52 · n 313 · Phase 3 · secondary NCT05259033

3-point MACE (% with event)

GZR101
—Not reported
IcoSema
—Not posted · NCT05013229
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. GZR101: 0 of 4 rows · IcoSema: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGZR101IcoSema
Dropout rate—
5.4%
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
3.8%
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Discontinued due to AEs—
—
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
—
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Serious AEs—
9.2%
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
11.1%
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Most frequent reported AEs—
nausea 23.8%
diarrhoea 15.8%
vomiting 10.6%
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
covid-19 15%
nausea 11.7%
diarrhoea 11.1%
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

IcoSema

Weight -3.71 vs 1.96 Insulin Icodec kg @ 52wk
absolute change · kg
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
0.89 vs -3.77 Semaglutide kg @ 52wk
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time in Range 75.9% (n=481) vs 61.9% (n=488) Insulin Icodec @ 52wk
absolute value · percentage points
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Below Range 0.27 vs 0.33 Insulin Icodec % of time @ 52wk
absolute value · % of time
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Above Range 23.2 vs 36.7 Insulin Icodec % of time @ 52wk
absolute value · % of time
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Fasting Plasma Glucose -1.9 vs -1.65 Insulin Icodec mmol/L @ 52wk
absolute change · mmol/L
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
-2.74 vs -1.41 Semaglutide mmol/L @ 52wk
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Hypoglycemia Episodes Level 2 or 3 15 vs 13 Semaglutide count @ 57wk
event count · count
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Hypoglycemia Episodes Level 2 15 vs 13 Semaglutide count @ 57wk
event count · count
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Hypoglycemia Episodes Level 3 0 vs 0 Semaglutide count @ 57wk
event count · count
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GZR101's landscape · IcoSema's landscape